Reply to F. Tomao et al

Affiliations

¹ Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France epujade@arcagy.org.
² Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany.
³ Instituto Valenciano de Oncologia, Valencia, Spain.

Comment

Eric Pujade-Lauraine et al. J Clin Oncol. 2014.

. 2014 Nov 1;32(31):3580.

doi: 10.1200/JCO.2014.57.7379. Epub 2014 Sep 2.

¹ Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France epujade@arcagy.org.
² Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany.
³ Instituto Valenciano de Oncologia, Valencia, Spain.

No abstract available

Comment on

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Pujade-Lauraine E, et al. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24637997 Clinical Trial.
Combination of bevacizumab and chemotherapy for platinum-resistant recurrent ovarian cancer: some observations about the AURELIA trial.
Tomao F, Tomao S, Benedetti Panici P. Tomao F, et al. J Clin Oncol. 2014 Nov 1;32(31):3580. doi: 10.1200/JCO.2014.57.6231. Epub 2014 Sep 2. J Clin Oncol. 2014. PMID: 25185105 No abstract available.